Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Oral BTK inhibitor shows continued promise for pemphigus

Key clinical point: A fast-acting, well-tolerated oral drug for pemphigus has advanced to a pivotal phase 3 trial.

Major finding: Of 15 patients, 6 had a complete response after 24 weeks on PRN1008, and another 4 still on treatment could get there.

Study details: The phase 2 BELIEVE trial included 27 pemphigus patients on an investigational oral BTK inhibitor for 12 weeks and 15 others treated for 24 weeks.

Disclosures: The presenter reported serving as a consultant to the study sponsor, Principia Biopharma.

Citation:

Murrell DF. EADV 2019.